Background: Acutely ill adults with hypoxaemic respiratory failure are at risk of lifethreatening hypoxia, and thus oxygen is often administered liberally. Excessive oxygen use may, however, increase the number of serious adverse events, including death. Establishing the optimal oxygenation level is important as existing evidence is of low quality. We hypothesise that targeting an arterial partial pressure of oxygen (PaO 2 ) of 8 kPa is superior to targeting a PaO 2 of 12 kPa in adult intensive care unit (ICU) patients with acute hypoxaemic respiratory failure.
| INTRODUC TI ON
Oxygen is essential to sustain human life and thus patients with acute hypoxaemic respiratory failure admitted to the intensive care unit (ICU) are all treated with supplemental inspired medical oxygen to avoid life-threatening hypoxia. In the ICU setting, oxygen therapy is guided by descriptive studies, 1,2 four small randomised clinical trials (RCTs) [3] [4] [5] [6] and small before-and-after trials, 7, 8 all indicating harmful effects of excessive oxygen supplementation. A recent meta-analysis of trials in acutely ill patients overall 9 underlined the potential detrimental effect of hyperoxaemia.
Nevertheless, the tendency in ICUs is towards a liberal use of oxygen therapy [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] and noteworthy, despite self-reported restrictive preferences among ICU nurses and physicians. [23] [24] [25] [26] Importantly, hypoxaemia is associated with increased mortality 10, 12, 18, 27 as it may lead to a low tissue oxygen tension (PO 2 ). The 'critical' tissue PO 2 however, defined as the value below which oxidative cellular metabolism fails, is not measurable in daily clinical practice, but it is as low as 0.13 kPa in isolated mitochondria. 28 Therefore, since only global oxygenation can be measured, liberal use of oxygen is likely to provide a too wide buffer of safety against life-threatening hypoxia. The potential harmful adverse effects of hyperoxaemia includes direct or indirect cellular damage mediated by reactive oxygen species, [29] [30] [31] [32] [33] hyperoxaemic vasoconstriction 34, 35 with following paradoxical risk of tissue hypoxia, and formation of absorption atelectases. [36] [37] [38] Targeting sub-normal oxygenation levels may, however, increase the risk of sudden desaturations due to the proximity to the steep slope of the oxygen dissociation curve. 39 This emphasises the importance of continuous pulse oximetry during restrictive oxygenation practices, and vigilance of the nursing staff to avoid or minimise episodes of definitive hypoxaemia. When such precautions are taken however, an oxygenation target of 8 kPa may be superior to the conventional liberal approach of oxygen supplementation observed in current clinical practice. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Restrictive oxygenation is recommended in patients with chronic obstructive pulmonary disease (COPD) outside the ICUs targeting an arterial oxygen saturation measured by pulse oximetry (SpO 2 ) of 88% to 92% 40, 41 ; in ICU patients with acute respiratory distress syndrome (ARDS) 'low normoxaemia'' defined as an arterial partial pressure of oxygen (PaO 2 ) from 7.3 to 10.7 kPa is often targeted, 42, 43 however, not recommended in current clinical guidelines due to lack of evidence. 44, 45 The optimal level of oxygenation in ICU patients remains unknown, especially when oxygenation levels are not definitively hyperoxaemic. Hence, trials in ICU patients comparing 'strict normoxaemia' defined as within the normal reference range of PaO 2 from approximately 10.7 to 13.3 kPa, 46 to 'low normoxaemia' are urgently needed.
A target PaO 2 of 8 kPa and a target PaO 2 of 12 kPa would both not a priori be considered beneficial or harmful. Therefore, whichever target performs best with respect to all-cause mortality, serious adverse events (SAEs), use of life support in the ICU and health-related quality-of-life has to be investigated in a large, pragmatic, randomised trial with the lowest possible risk of bias.
We hypothesise that targeting a PaO 2 of 8 kPa reduces 90-day mortality compared with targeting a PaO 2 of 12 kPa in adult patients with hypoxaemic respiratory failure who are acutely admitted to the ICU.
| ME THODS

| Trial design
The Handling Oxygenation Targets in the ICU (HOT-ICU) trial is an investigator-initiated, pragmatic, international, multicentre, randomised, outcome-assessor blinded, parallel-group trial of a lower oxygenation target vs a higher oxygenation target in adult patients with acute hypoxaemic respiratory failure acutely admitted to the ICU. Patients are randomised 1:1 within 12 hours after ICU admission and stratified by site, known COPD, and active haematological malignancy.
The protocol has been written according to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 statement. 47 The SPIRIT 2013 checklist is presented in Appendix quality-of-life at 1-year follow-up as well as 1-year cognitive and pulmonary function in a subgroup; and an overall health economic analysis. To detect or reject a 20% relative risk reduction, we aim to include 2928 patients. An interim analysis is planned after 90-day follow-up of 1464 patients.
Conclusion:
The HOT-ICU trial will test the hypothesis that a lower oxygenation target reduces 90-day mortality compared with a higher oxygenation target in adult ICU patients with acute hypoxaemic respiratory failure.
Editorial Comment
This is the protocol for the largest ongoing multinational randomised clinical trial on higher vs lower oxygenation targets in the ICU. It is set to be one of the most important ICU trials, guiding oxygenation targets for critically ill patients globally. S1. A preliminary systematic review on the effect of lower vs higher oxygenation targets on mortality, including a trial sequential analysis was conducted 48 as recommended. 49, 50 The preliminary analysis revealed no evidence to support neither a high nor a low oxygenation target.
| Registration
The trial was prospectively registered at European clinical trials database (EudraCT number 2017-000632-34) and at ClinicalTrials.gov (Identifier: NCT03174002), registered June 2, 2017.
| Setting
Intensive care units in university and non-university hospitals in Denmark, Finland, the Netherlands, Norway, Switzerland, the United Kingdom and Iceland that admit adult patients. A complete list of including sites can be found at ClinicalTrials.gov (Identifier: NCT03174002). 
| Inclusion criteria
| Exclusion criteria
Patients will be excluded from the trial if they meet any of the 
| Screening and randomisation
All patients fulfilling the inclusion criteria within 12 hours from ICU admission will be screened by local investigators using a central web-based screening system. Patients are eligible if they fulfil all inclusion criteria and none of the exclusion criteria. Eligible patients will be randomised 1:1 via the screening system using a computer-generated allocation sequence list according to the stratification variables, and permuted blocks of varying sizes; all processes are concealed for patients, clinicians and trial investigators.
Inclusion and exclusion of patients will be reported as according to the Consolidated Standards of Reporting Trials (CONSORT) statement. 51
| Interventions
Enrolled patients will be randomly allocated to a PaO 2 oxygenation target equal to 8 kPa (60 mm Hg) or a PaO 2 oxygenation target equal to 12 kPa (90 mm Hg) throughout the length of stay in the ICU, including any readmissions up until 90 days from randomisation. The oxygenation target will be achieved by titration of the FiO 2 from 0.21 to 1.00 in both intervention groups. Deviation above the allocated oxygenation target will be allowed only if FiO 2 = 0.21 and deviation below the allocated oxygenation target will be allowed only if FiO 2 = 1.00. Given the pragmatic design of the trial, choice of oxygen supplementation devices and ventilator settings other than the FiO 2 are at the discretion of the treating clinicians. Ventilator settings will be registered daily enabling assessment of any intervention group differences other than the FiO 2 , in the subgroup of mechanically ventilated patients. In both intervention groups, additional oxygen supplementation during ICU procedures, as well as during transportation, surgery and radiological examinations will be at the discretion of the treating clinicians; however, it will be requested to maintain the assigned oxygenation target whenever possible. Pre-oxygenation with FiO 2 = 1.0 prior to or during endotracheal procedures should be avoided if possible, alternatively, pre-oxygenation for a maximum duration of 1 minute prior to endotracheal suction and for a maximum duration of 3 minutes prior to intubation is allowed.
| Withdrawal and discontinuation of trial intervention
Patients will be withdrawn from the trial intervention at any time if informed consent is retracted or not given as according to national regulations. Data registration from a withdrawn patient will continue, unless consent for this is also withdrawn. If a patient experiences a suspected unexpected serious adverse reaction (SUSAR) related to oxygen supplementation, the patient will be withdrawn from the trial immediately; data registration will, however, continue.
In all withdrawn patients, trial intervention will be stopped and further oxygen supplementation in the ICU will be at the discretion of the treating clinicians. Patients withdrawn from the trial, were data can be acquired as according to national regulations, will be followed up and included in the intention-to-treat analyses as well as in the per-protocol analyses if the criteria for these are met.
Patients transferred to an ICU participating in the HOT-ICU trial will keep the allocated oxygenation target during ICU admission up until 90 days after randomisation. Patients transferred to an ICU not participating in HOT-ICU will be considered discharged from the ICU. All patients will be followed up for the primary outcome, and for as many of the secondary outcomes as possible through national registers, phone calls, and/or patient charts.
A patient can be discontinued from the intervention by the clinicians at any time if the patient experiences intolerable adverse events believed to be related to the trial intervention. In these cases, the oxygenation target should be reinstalled if the trial intervention at a later point is considered safe by the treating clinicians. In either case, the patient remains in the trial and will be included in the intention-to-treat population, and per-protocol populations if the criteria are met.
Flawed randomisations, that is, patients found not to have fulfilled the inclusion criteria at randomisation, or who fulfilled one or more of the exclusion criteria at randomisation, will remain in the trial.
| Outcome measures
The primary outcome measure is all-cause mortality 90 days after The specific elements of the above composite outcomes will be reported in a supplement to the primary publication.
An overview of the enrolment, interventions and assessments procedures as according to the SPIRIT 2013 statement 47 is presented in Table 1 .
| Blinding
The trial intervention is not blinded for investigators, clinicians or patients. The primary outcome of 90-day mortality will be drawn from electronic patient systems relying on central national registers and will thus be assessed blinded. Similar procedure is applied for the secondary outcome of 1-year mortality. EQ-5D-5L and RBANS interviews, as well as pulmonary function tests will be conducted by research staff members who are not employed in the ICUs, without access to the eCRF or patient files and thus blinded to the trial interventions. Since local investigators will provide all other outcomes from the patients' medical files, blinding of outcome assessment is not feasible for these remaining outcomes. The trial statistician will be blinded for the allocation during all analyses. The members of the data monitoring and safety committee (DMSC) will remain blinded unless 1) they request otherwise or 2) the interim analysis has provided strong indications of one of the interventions being harmful.
The writing committee will remain blinded for the allocation while drafting the abstract for the primary publication.
| Subgroups
We will compare the primary outcome measure in five predefined 
| Data registration and monitoring
All data will be entered into a central web-based, password protected, encrypted electronic case report form (eCRF) system supplied and supported by the Copenhagen Trial Unit using the clinical Full external monitoring of registered data is applied at all trial sites following a monitoring plan developed in collaboration with the good clinical practice (GCP) unit at Aalborg and Aarhus University Hospitals according to GCP standards. 54 Central monitoring is done by Sponsor using the eCRF data only. 
| Adverse and serious adverse events
Baseline variables (general patient information, respiratory support, respiratory status, acute illness parameters, SOFA score and chronic comorbidities)
X X Mortality X X
Serious adverse events in the ICU X
Days alive without organ support X
Days alive and out of hospital X
EuroQol (EQ-5D-5L) X
Neuropsychological function (RBANS) X*
Pulmonary function X* allocated oxygenation target. If a relation is suspected an automatic warning will be sent to the coordinating centre, hereby enabling the Sponsor to continuously evaluate trial safety and to decide whether it represents a serious adverse reaction or SUSAR and act accord-
ingly. Any other SAEs according to the International Conference on
Harmonisation of technical requirements for registration of pharmaceuticals for human use GCP (ICH-GCP) definition 54 will not be systematically recorded, but will be evaluated continuously by primary site investigators and co-investigators in their daily clinical practice.
The three adverse reactions to normobaric medical oxygen are atelectasis, pleuritis and ARDS 55 ; all common in critically ill patients admitted to the ICU with acute hypoxaemic respiratory failure. They are therefore indistinguishable from the adverse events caused by the underlying pulmonary pathophysiology. However, differences in the severity of atelectasis and of ARDS will be captured by daily registrations of FiO 2 and PaO 2 enabling the calculation of a PaO 2 / FiO 2 ratio.
If a patient experiences a SUSAR, this will be reported to the relevant authorities as required by the national and European regulations.
All trial sites have insurances for participating patients either through the national health insurances or through specifically supplied local trial insurances as required according to the specific trial sites and national regulations.
| Approvals
The 
| Statistics
The primary analysis will be conducted in the intention-to-treat population 56 being all randomised patients except those were follow-up cannot be conducted due to withdrawal of consent as according to national regulations. 54, 57, 58 The primary outcome of 90-day mortality in the intervention groups will be compared using a generalised linear model with a log-link and binomial error distribution with adjustment for stratification variables (site, known COPD and active haematological malignancy). 59 Significance of the intervention will be assessed based on P-values from this regression analysis and risk ratios with 95% confidence intervals are readily available from it.
The primary analysis will be supplemented with Kaplan-Meier plots (not accounting for stratification variables) and Cox proportional hazard models with adjustment for stratification variables.
A secondary analysis will be performed adjusting for the stratification variables and for major prognostic baseline differences: age, active metastatic cancer, type of admission (medical, elective surgical or emergency surgical) and baseline Sequential Organ Failure Assessment (SOFA) score. 60 One pre-planned sensitivity analysis will be conducted in the perprotocol population defined as all patients except those with one or more major protocol violations (MPVs); that is, both the highest and the lowest registered PaO 2 in one 12-hour interval from 06:00 to 18:00 or from 18:00 to 06:00 are at least 1. with MPVs, which draws the oxygenation groups away from each other, will be removed.
A two-sided P value of less than 0.05 will be considered statistically significant. P-values for the secondary outcomes will be adjusted for multiple testing. We will present the intervention effect expressed as relative risk with 95% CIs in the overall population as well as in the planned subpopulations.
A predefined detailed statistical analyses plan including models for all secondary outcomes will be provided in a separate publication submitted prior to inclusion of last patient, or in the case that the trial is prematurely terminated, submitted prior to closure of the trial database.
| Sample size calculations
To detect or reject a true 20% relative risk reduction, achieving a maximal type 1 error of 5% and type 2 error (power) of 90%, we will randomise 2928 patients. The sample size estimation was based on a control group 90-day mortality (target PaO 2 of 12 kPa) of 25% 27, 61 and allocation 1:1 to the two groups. We will be able to detect or refute an absolute risk reduction of 5% point or more, corresponding to a number needed to treat of 20 or less. To maintain power in the statistical analysis, we will adjust the primary analyses for the stratification variables.
| Data monitoring and safety committee (DMSC)
An independent DMSC will oversee the trial during the trial period following the predefined Charter for the DMSC (Appendix S3).
A planned interim analysis will be conducted when the first 1464 patients (50% of the sample size) have completed 90-day follow-up.
The DMSC may request unplanned interim analyses at any time.
| Availability of data and material
The clean electronic trial database file will be delivered to the EudraCT Database and to the Danish Data Archive. All trial documents, including protocol amendments will be available on the public HOT-ICU trial website (www.cric.nu/hot-icu) and communicated to relevant parties through monthly newsletters. The trial results will be sought published in a relevant peer reviewed scientific journal and linked to the trial website.
| D ISCUSS I ON
Oxygen is a medicine that has been used for decades with a continuing tendency towards liberal use. This is highlighted in recently published observational studies in critically ill patients admitted to ICUs in Europe, 19, 27 in New Zealand and Australia 12 and in the US, 18 all showing U-shaped associations between arterial oxygenation and mortality. Noteworthy, the PaO 2 associated with the lowest mortality was highly variable in these studies-from 10 kPa 27 to as high as 40 kPa. 18 Taking the observational study design into consideration however, causality cannot be assumed, and the associations found may merely represent differences in disease severity or be reflections of the preferred oxygenation levels in the included ICUs. Therefore, the optimal target interval result- The choice of protocolling a fixed normoxaemic oxygenation target in the control group rather than standard care at clinicians' discretion is based on the large variation in oxygenation levels observed in ICU cohorts worldwide with median and mean PaO 2 levels ranging from 9.8 to 23.0 kPa. [10] [11] [12] [14] [15] [16] 18 As the HOT-ICU trial is international, a highly variable approach to oxygen supplementation can be assumed, thus a non-protocolled standard care in the control group would induce a risk of masking any deductions about the actual oxygenation strategy used. Furthermore, a pilot trial 4 which confirmed equipoise of the intervention groups in the HOT-ICU trial, used a protocolled oxygenation target in the liberal oxygenation control group, a target that corresponds to the higher oxygenation target of 12 kPa in the HOT-ICU trial.
The choice of mortality as primary outcome is based on the high mortality rates in ICU patients 70 and in mechanically ventilated patients in particular, 71 and on the probability of detecting a difference in mortality by interventions in the ICU, especially for life-support interventions. Only mortality as the primary outcome will weigh the totality of the potential positive and negative effects of a higher vs a lower oxygenation strategy. Finally, the recent systematic review, 9
which suggested reduced all-cause mortality with conservative oxygen therapies in acutely ill patients overall, further justifies the choice of mortality as the primary outcome.
| PER S PEC TIVE
The design of the HOT-ICU trial aims to minimise the risk of systematic errors and the trial will provide valuable information on benefits and/or harmful effects of an oxygenation target of either 8 kPa or an oxygenation target of 12 kPa in patients acutely admitted to the ICU with need of oxygen supplementation due to hypoxaemic respiratory failure, including both short-term and long-term outcomes. Being the largest trial on the subject, the trial will add considerably to the cumulated evidence and to the overall knowledge of optimal oxygenation targets in the ICU, with the potential to reduce both mortality and morbidity as well as costs in the ICU. The HOT-ICU trial will assist in guiding future clinical practice, ensuring a more evidence-based use of medical oxygen in the ICU.
| TRIAL S TATUS
The trial is currently recruiting at 28 active sites. 
